Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Go back to Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)| (NASDAQ: ABSI) | Delayed: 8.16 -0.05 (0.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.21 | 52 Week High | $ | |||
| Open | $8.03 | 52 Week Low | $ | |||
| Day High | $8.25 | P/E | N/A | |||
| Day Low | $8.02 | EPS | $ | |||
| Volume | 1,353,626 | |||||
